Total submissions: 4
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV002548668 | SCV003035305 | likely benign | not provided | 2024-01-03 | criteria provided, single submitter | clinical testing | |
Gene |
RCV002548668 | SCV003805016 | uncertain significance | not provided | 2022-08-18 | criteria provided, single submitter | clinical testing | Not observed at significant frequency in large population cohorts (gnomAD); In silico analysis supports that this variant does not alter splicing; Has not been previously published as pathogenic or benign to our knowledge |
Ambry Genetics | RCV004619679 | SCV005116347 | uncertain significance | Hereditary cancer-predisposing syndrome | 2024-04-11 | criteria provided, single submitter | clinical testing | The c.1390+5G>A intronic variant results from a G to A substitution 5 nucleotides after coding exon 9 in the FH gene. This nucleotide position is highly conserved in available vertebrate species. In silico splice site analysis predicts that this alteration will not have any significant effect on splicing. Based on the available evidence, the clinical significance of this variant remains unclear. |
Natera, |
RCV001373130 | SCV002085290 | uncertain significance | Fumarase deficiency | 2021-10-11 | no assertion criteria provided | clinical testing |